Table 1.
Patient characteristics
| Variable | Total N (%) |
Survival ≥ 1 year post relapse N (%) |
|---|---|---|
| Number of patients | 1788 | 413 |
| Year of HCT | ||
| 1990–2000 | 745 (42) | 203 (49) |
| 2001–2010 | 1043 (59) | 210 (51) |
| HCT during CR1 | 1249 (70) | 312 (76) |
| CR2 | 539 (30) | 101 (24) |
| Age | ||
| Median (range) | 32 (<1–76) | 30 (1–75) |
| 0–18y | 613 (34) | 136 (33) |
| 19–40y | 439 (25) | 138 (33) |
| 41–76y | 736 (41) | 139 (34) |
| AML type | ||
| De novo | 1450 (81) | 348 (84) |
| Secondary | 276 (15) | 47 (11) |
| Missing | 62 (3) | 18 (4) |
| Cytogenetics scoring | ||
| Favorable | 138 (8) | 45 (11) |
| Intermediate / normal | 805 (45) | 190 (46) |
| Unfavorable | 334 (19) | 52 (13) |
| Missing | 511 (29) | 126 (31) |
| Myeloablative | 1374 (77) | 337 (82) |
| RIC/NMA | 414 (23) | 76 (18) |
| Graft type | ||
| Bone marrow | 935 (52) | 240 (58) |
| Peripheral blood | 621 (35) | 138 (33) |
| Cord blood | 232 (13) | 35 (8) |
| Donor type | ||
| HLA-id sibling | 936 (52) | 245 (59) |
| URD well matched | 317 (18) | 69 (17) |
| URD partially matched | 134 (7) | 35 (8) |
| URD mismatched | 56 (3) | 7 (2) |
| URD unknown | 113 (6) | 22 (5) |
| Cord blood | 232 (13) | 35 (8) |
| GVHD prophylaxis | ||
| ATG/alemtuzumab | 406 (23) | 80 (19) |
| Ex-vivo T cell depletion | 48 (3) | 12 (3) |
| CSA/tac ± other | 1334 (75) | 321 (78) |
| Time from HCT to relapse | ||
| Median (range) | 7 (1–177) | 14 (1–177) |
| < 6m | 774 (43) | 88 (21) |
| 6m–2y | 702 (39) | 191 (46) |
| 2–3y | 138 (8) | 52 (13) |
| ≥3y | 174 (10) | 82 (20) |
| AML relapse site | ||
| Extramedullary only | 80 (4) | 25 (6) |
| Bone Marrow ± other sites | 1046 (59) | 200 (48) |
| Not reported/missing | 662 (37) | 188 (44) |
| Active GVHD prior to relapse | ||
| Yes | 727 (41) | 170 (41) |
| No | 1028 (57) | 234 (57) |
| Missing | 33 (2) | 9 (2) |
| Treatment for relapse | ||
| 2nd HCT±chemo±DLI | 369 (21) | 182 (44) |
| DLI±chemo | 202 (11) | 57 (14) |
| Chemo only | 660 (37) | 87 (21) |
| Supportive care/no therapy | 357 (20) | 35 (8) |
| Missing | 200 (11) | 52 (13) |
| Response to therapy | ||
| CR | 271 (15) | 165 (40) |
| No response | 704 (39) | 121 (29) |
| Missing | 813 (45) | 127 (31) |
| Surviving at last follow-up | 229 (13) | 173 (42) |
| Median follow-up after relapse, months | 39 (<1–193) | 59 (12–193) |